EurOPDX

The EurOPDX Consortium of translational and clinical researchers focuses on the use and evolution of patient-derived cancer xenograft models.

[canSERV @canSERV_EU]

Going global?: Can #canSERV_EU bring world-class knowledge and resources together?

Prof. Lillian Siu, Senior Med. Oncologist at Princess Margaret Cancer Centre and Prof of Medicine at the Univ of Toronto, discusses the potential for canSERV to go global.

https://t.co/vuV27vwauA

[Euro-BioImaging ERIC @EuroBioImaging]

#LoveData25 Whether you're just starting out in the field or are a seasoned expert, the #EuroBioImaging Image Data Community Days will provide valuable discussions and learning opportunities for everyone. We hope you will join us from 🗓️ April 7-11 online.
Free & Open to all!
Register & more info 🔽
https://t.co/p2NEy31qYQ

[Digestive Cancers Europe @dice_europe]

To kick off #ECCAM2025, we will hold a webinar on 🗓️27 February at ⏰10 am CET focusing on the rise of #CRC in the younger population.

The key topics on the agenda are:
🔹Understanding the rise of early-onset #ColorectalCancer in 🇪🇺
🔹The💬 personal experience of a young person living with CRC
🔹Addressing ⚠️risk factors, early symptoms, and screening barriers
🔹How to 📚educate youth on symptoms & screening

We hope to see you there, as this topic is relevant to all of us. To register👉 https://t.co/MHBwZzNyvg

[Science Magazine @ScienceMagazine]

When asked to draw a scientist, school-age kids in the United States are increasingly sketching women, according to a study from 2018.

Read more on #WomenInScienceDay: https://t.co/gv6TDrdT4r

[EMBL @embl]

📢Calling female African scientists.

Applications open for the EMBL-UNESCO residencies in infection biology:
🪴Grow your network
🧪Develop your skills
🧠Exchange knowledge with international colleagues

Deadline 31 March 2025
https://t.co/2aFhlTpEFa
#WomenInSTEM #WomenInScience

[United Nations @UN]

The world needs science, and science needs women. 👩‍🔬🧪

Yet, they remain under-represented and struggle to get recognition for their achievements.

More from @UNESCO on Tuesday’s International Day of Women & Girls in Science: https://t.co/Jm8nwQuhzC

[Manchester Cancer Research Centre @MCRCnews]

⭐ Digital Infrastructure Scientist – closing today!

Exciting role for a PhD graduate in computing, stats, or data science to impact digital healthcare in oncology & radiotherapy.

🔗Apply now: https://t.co/BLge6iG17z

[Euro-BioImaging ERIC @EuroBioImaging]

The Euro-BioImaging Scientific Ambassador programme provides training 👩‍🔬 , networking opportunities & travel grants 🧳 to individuals who are passionate about imaging 🔬and want to help spread the word about #EuroBioImaging. Early career researchers are encouraged to apply. Apply by February 17.
Learn more:
https://t.co/BZluGOl1hO

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🔴 Targeting tumor metabolism as a potential therapeutic strategy in MTAP-deleted cancer.

🗞️ Recently published in @NatureComms: results from a first-in-human, phase I clinical trial 👉 https://t.co/Rh7WLYqHTx

#UITM @CaixaResearch

[ESMO - Eur. Oncology @myESMO]

📣 #ESMOBreast25: Time is running out! Last chance to submit your abstract! Showcase your research to global experts and help us shape the future of breast cancer.

⏰ Abstract submission deadline 11 February 2025

🔗 https://t.co/ymPs3jJwTp

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🗞️ Published in @CellRepMed, the results of a VHIO-led study show that the #RAD51 biomarker could complement next-generation sequencing in personalising prostate cancer treatment. 

➡️ https://t.co/CLWk5KzxS7

[World Health Organization (WHO) @WHO]

Today is International Day of Women & Girls in Science.

Marie Curie, the first woman to win a @NobelPrize. Her contributions have left an indelible mark on the world of science & health & continue to inspire generations of scientists & innovators. 🔬 #WomenInScience #WomenInSTEM

[CRUK Cambridge Institute @CRUK_CI]

Finding balance⚖️

Leading a lab pulls you in many directions, managing research alongside mentoring the next generation.

For International Day of Women & Girls in Science tomorrow, we asked PIs to share their advice on scientific leadership.

@CRUKresearch @Cambridge_Uni

[Sara Gutiérrez-Enríquez @SaraGutierrezEn]

Refining the interpretation of variants of uncertain significance in hereditary cancer screening through integrated RNA sequencing - Genetics in Medicine Open https://t.co/Obp1XplmhJ

[The ICR @ICR_London]

With the news that #ProstateCancer is now the most common cancer in England, there's been a lot of discussion about improving early diagnosis.

At the ICR, we're researching new ways to identify men earlier who are at the highest risk of the disease ⤵️

https://t.co/TahFy13lDs

[Euro-BioImaging ERIC @EuroBioImaging]

Are you passionate about open science and imaging? Want to expand your network & learn new skills? Check out #EuroBioImaging’s Scientific Ambassador programme, a great way to make a positive impact while enhancing your own career. On top of training, networking, personalised support and guidance, Scientific Ambassadors will benefit from travel grants, thanks to the #EVOLVEproject.
#ECR are particularly encouraged to apply.
Apply by February 17.
Learn more:
https://t.co/BZluGOl1hO

[EMBO @EMBO]

Open call! The EMBO Global Investigator Network supports group young leaders who are setting up their laboratories in Chile, India, Singapore or Taiwan. Apply by 1 May: https://t.co/9aZwpztwP9
#ResearchFunding #LifeSciences

[Vall d'Hebron @vallhebron]

🔬 Nova @VHIO Talks | Noves estratègies davant del càncer!

💡 Teràpia gènica, vacunes i modificació de l’ADN de les cèl·lules tumorals. Quins són els avenços més prometedors?

🎤 En parlem amb @alena_grosvidal, @barrigafm i Julia Lostes en un debat moderat per @luis_quevedo.

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🔴 Potentially practice-changing results point to new standard-of-care treatments for patients with metastatic colorectal cancer.

🔬 Results of two phase 3 clinical studies, co-authored by VHIO investigators, were presented today at @ASCO #GI25 👉 https://t.co/yezvwWLJVq

[Cancer_Evolve @cancer_evolve]

PROSTATE: in patients with a BRCA1/2 or PALB2 mutation receiving PARP inhibition for advanced disease, progression was associated with reversion mutation in 79% of cases; in those with homozygous deletions, selection for wild-type clones was observed.
https://t.co/OL2AtEwMUL